CHF and arrhythmias:
Indications for: TRULICITY
As adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus (T2DM).
Adult Dosage:
Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. Initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.
Children Dosage:
Not established.
TRULICITY Contraindications:
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Boxed Warning:
Risk of thyroid C-cell tumors.
TRULICITY Warnings/Precautions:
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.
TRULICITY Classification:
Glucagon-like peptide-1 (GLP-1) receptor agonist.
TRULICITY Interactions:
Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.
Adverse Reactions:
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.
Drug Elimination:
Half-life: ~5 days.
Generic Drug Availability:
NO
How Supplied:
Single-dose pen—4
Diabetes:
Indications for: TRULICITY
As adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus (T2DM).
Limitations of Use:
Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes mellitus. Not recommended in patients with severe GI disease (including severe gastroparesis).
Adult Dosage:
Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.
Children Dosage:
<10yrs: not established. Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥10yrs: initially 0.75mg once weekly. If additional glycemic control is needed, may increase to max 1.5mg once weekly after ≥4 weeks on the 0.75mg dose.
TRULICITY Contraindications:
History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.
Boxed Warning:
Risk of thyroid C-cell tumors.
TRULICITY Warnings/Precautions:
Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.
TRULICITY Classification:
Glucagon-like peptide-1 (GLP-1) receptor agonist.
TRULICITY Interactions:
Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.
Adverse Reactions:
Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.
Drug Elimination:
Half-life: ~5 days.
Generic Drug Availability:
NO
How Supplied:
Single-dose pen—4
